CORINDUS VASCULAR ROBOTICS, INC. (NYSEMKT:CVRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02.Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers;Compensatory
Arrangement of Certain Officers.

On March 6, 2017, Louis Cannon, MD, FACC, FACP, FACA, FCCP was
added to the Board of Directors of Corindus Vascular Robotics,
Inc. (the Company) and began his service as a Class I director of
the Company until such time as he will stand for election at the
Companys 2017 annual meeting of stockholders. Dr. Cannon is a
practicing Interventional Cardiologist for the Michigan Heart and
Vascular Specialists and a recognized leader in cardiovascular
research and development. Dr. Cannon is also the founder and
Senior Managing Director of BioStar Ventures III, LLC, the
general partner of BioStar Ventures III L.P. (BioStar), one of
several investors in the previously announced financing of
approximately $45 million (the Financing), in which BioStar has
agreed to purchase 7,557,436 shares at $0.6616 per share. Dr.
Cannon will also serve as a member of the Boards Audit Committee,
Compensation Committee and Nominating and Governance Committee.
As previously disclosed, Dr. Cannon was elected by the Board to
fill a vacancy created by directors who resigned in connection
with the Financing.

As with its other directors, the Company intends to enter into
its standard form of indemnification agreement with Dr. Cannon,
which, among other things, provides for indemnification to the
fullest extent permitted by the laws of the State of Delaware,
advancement of legal fees and expenses in connection with legal
proceedings, certain procedures for determining whether he is
entitled to indemnification and dispute resolution procedures.

Dr. Cannon will also participate in the Companys non-employee
director compensation policy, as filed with the Companys Form
10-Q filed November 9, 2016. Dr. Cannon will also be entitled to
reimbursement for certain customary business expenses in
connection with attending board meetings.

Other than as noted above, there are no transactions to which the
Company is a party and in which Dr. Cannon has a material
interest that is required to be disclosed under Item 404(a) of
Regulation S-K. Dr. Cannon has not previously held any positions
with the Company and has no family relationships with any
directors or executive officers of the Company.

About CORINDUS VASCULAR ROBOTICS, INC. (NYSEMKT:CVRS)

Corindus Vascular Robotics, Inc. designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit. At the bedside, the CorPath System’s robotic drive and sterile, single-use cassette (CorPath Cassette) translate the physician’s commands into movements and manipulations of the coronary stents and catheters.

CORINDUS VASCULAR ROBOTICS, INC. (NYSEMKT:CVRS) Recent Trading Information

CORINDUS VASCULAR ROBOTICS, INC. (NYSEMKT:CVRS) closed its last trading session down -0.07 at 1.19 with 1,736,797 shares trading hands.